Literature DB >> 1842413

Reversibility of cardiac fibrosis in mice chronically infected with Trypanosoma cruzi, under specific chemotherapy.

S G Andrade1, S Stocker-Guerret, A S Pimentel, J A Grimaud.   

Abstract

UNLABELLED: This investigation was performed to verify the effect of specific chemotherapy (Benznidazole or MK-436) on the inflammatory and fibrotic cardiac alterations in mice chronically infected with the strains 21 SF (Type II) and Colombian (Type III) of Trypanosoma cruzi. To obtain chronically infected mice, two groups of 100 Swiss mice each, were infected with either the 21 SF or the Colombian strain (2 x 10(4) and 5 x 10(4) blood forms respectively). The rate of mortality in the acute phase was of 80% for both groups. Twenty surviving mice chronically infected with the 21 SF strain and 20 with the Colombian strain were then divided in treated and untreated groups. Excluding those that died during the course of treatment, 14 mice chronically infected with the 21 SF strain and 15 with the Colombian strain were finally evaluated in the present study. Chemotherapy was performed with Benznidazole (N-benzil-2-nitro-1-imidazolacetamide) in the dose of 100 mg/k.b.w/day, for 60 days, or with the MK-436 (3(1-methyl-5 nitroimidazol-2-yl) in two daily doses of 250 mg/k.b.w, for 20 days. Parasitological cure tests were performed (xenodiagnosis, haemoculture, subinoculation of the blood into newborn mice), and serological indirect immunofluorescence test. The treated and untreated mice as well as intact controls were killed at different periods after treatment and the heart were submitted to histopathological study with hematoxilineosin and picrosirius staining; ultrastructural study; collagen immunotyping, fibronectin and laminin identification by immunofluorescence tests.
RESULTS: the untreated controls either infected with 21 SF or Colombian strain, showed inflammatory and fibrotic alterations that were mild to moderate with the 21 SF strain and intense with the Colombian strain. Redpicrosirius staining showed bundles of collagen in the interstitial space and around cardiac fibers. Increased deposits of matritial components and collagen fibers, macrophages and fibroblasts appeared at the ultrastructural examination. Deposits of fibronectin, laminin, pro-III and IV collagens were seen, most intense in those infected with the Colombian strain. Treated mice, parasitologically cured, presented clear-cut regression of the inflammatory lesions and of the interstitial matrix thickening. Mice infected with the Colombian strain and treated with MK-436, was parasitologically cured in 5/6 cases and showed mild inflammatory infiltration and fibrosis. The mice treated with Benznidazole (Colombian strain) did not cure and showed moderate fibrosis and inflammation. Treatment of the mice infected with the 21 SF with Benznidazole determined parasitological cure of all animals, that showed mild inflammation and fibrosis of the myocardium.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1842413     DOI: 10.1590/s0074-02761991000200008

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  23 in total

1.  Vaccine-Linked Chemotherapy Improves Benznidazole Efficacy for Acute Chagas Disease.

Authors:  Kathryn Jones; Leroy Versteeg; Ashish Damania; Brian Keegan; April Kendricks; Jeroen Pollet; Julio Vladimir Cruz-Chan; Fabian Gusovsky; Peter J Hotez; Maria Elena Bottazzi
Journal:  Infect Immun       Date:  2018-03-22       Impact factor: 3.441

2.  Detection of parasitemia profiles by blood culture after treatment of human chronic Trypanosoma cruzi infection.

Authors:  Ana Maria de Castro; Alejandro Ostermayer Luquetti; Anis Rassi; Egler Chiari; Lúcia Maria da Cunha Galvão
Journal:  Parasitol Res       Date:  2006-03-29       Impact factor: 2.289

3.  "Autoimmune rejection" of neonatal heart transplants in experimental Chagas disease is a parasite-specific response to infected host tissue.

Authors:  R L Tarleton; L Zhang; M O Downs
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

4.  Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.

Authors:  Simone Garcia; Carolina O Ramos; Juliana F V Senra; Fabio Vilas-Boas; Maurício M Rodrigues; Antonio C Campos-de-Carvalho; Ricardo Ribeiro-Dos-Santos; Milena B P Soares
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

5.  Depletion of T-cell subpopulations results in exacerbation of myocarditis and parasitism in experimental Chagas' disease.

Authors:  R L Tarleton; J Sun; L Zhang; M Postan
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

6.  Benznidazole treatment following acute Trypanosoma cruzi infection triggers CD8+ T-cell expansion and promotes resistance to reinfection.

Authors:  Bianca Perdigão Olivieri; Vinícius Cotta-De-Almeida; Tania Araújo-Jorge
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

Review 7.  Design or screening of drugs for the treatment of Chagas disease: what shows the most promise?

Authors:  Galina I Lepesheva
Journal:  Expert Opin Drug Discov       Date:  2013-09-30       Impact factor: 6.098

8.  Pharmacokinetics and Tissue Distribution of Benznidazole after Oral Administration in Mice.

Authors:  Luísa Perin; Rodrigo Moreira da Silva; Kátia da Silva Fonseca; Jamille Mirelle de Oliveira Cardoso; Fernando Augusto Siqueira Mathias; Levi Eduardo Soares Reis; Israel Molina; Rodrigo Correa-Oliveira; Paula Melo de Abreu Vieira; Cláudia Martins Carneiro
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

9.  Changing Epidemiology and Approaches to Therapy for Chagas Disease.

Authors:  Louis V. Kirchhoff
Journal:  Curr Infect Dis Rep       Date:  2003-02       Impact factor: 3.725

10.  Impact of dual infections on chemotherapeutic efficacy in BALB/c mice infected with major genotypes of Trypanosoma cruzi.

Authors:  H R Martins; R Moreira Silva; H M S Valadares; M J O Toledo; V M Veloso; D M Vitelli-Avelar; C M Carneiro; G L L Machado-Coelho; M T Bahia; O A Martins-Filho; A M Macedo; M Lana
Journal:  Antimicrob Agents Chemother       Date:  2007-07-16       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.